 |
| Global Endocrine Therapy Drugs (ETDS) Market Size |
Endocrine therapy drugs are used to treat hormone-sensitive cancers such as
breast cancer, prostate cancer and ovarian cancer by blocking the body's
natural hormones or by lowering hormone levels. These drugs play an important
role in the long-term treatment and management of various cancers. With rising
cancer cases worldwide, the need for effective endocrine therapy drugs has
increased significantly.
The global Endocrine
Therapy Drugs (ETDS) Market is estimated
to be valued at US$ 35060.96 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period
2024 to 2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
One of the key trends driving the growth of the Endocrine Therapy Drugs (ETDS)
Market is the increasing prevalence of
cancer globally. According to WHO, cancer is the second leading cause of death
worldwide and the number of new cancer cases is expected to rise by over 70% in
the next two decades. Breast cancer is the most common cancer in women with
over 2 million new cases diagnosed in 2018 alone according to global cancer
statistics. Rising pollution levels, changing lifestyle habits and growing
geriatric population are major factors contributing to the increasing burden of
cancer worldwide which in turn is fueling the demand for effective drugs like
endocrine therapy drugs for long term treatment of cancer patients. This
growing prevalence of cancer is expected to accelerate the growth of the Endocrine
Therapy Drugs (ETDS) Market over the
forecast period.
Segment Analysis
The global Endocrine Therapy Drugs (ETDS) Market is dominated by hormone therapy sub-segment.
Hormone therapy is the most common type of endocrine therapy used to treat
hormone receptive breast cancer. It involves using drugs to block the effects
of estrogen or progesterone on breast cancer cell growth. Hormone therapy is
very effective in treating hormone-receptive breast cancers as it targets the
specific hormones that help cancer cells grow.
Key Takeaways
Global
Endocrine Therapy Drugs (ETDS) Market Size is expected to witness high
growth over the forecast period of 2024 to 2031. The global Endocrine Therapy
Drugs (ETDS) Market is estimated to be
valued at US$ 35060.96 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period
2024 to 2031.
Regional Analysis
North America currently dominates the global Endocrine Therapy Drugs (ETDS)
Market due to rising prevalence of
breast cancer and presence of major market players. According to American
Cancer Society, over 276,480 new cases of breast cancer were diagnosed in the
US in 2022. The region is expected to continue its dominance over the forecast
period owing to growing adoption of advanced hormone therapies and increasing
research investments for new drug development.
Key Players Analysis
Key players operating in the Endocrine Therapy Drugs (ETDS) Market are Johnson & Johnson (US), Procter &
Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao
Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation
(Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group
Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First
Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). Johnson &
Johnson and Procter & Gamble currently hold majority market share due to
their diverse hormone therapy drug portfolio and strong global presence.
Explore More Related Article On This
Topic: https://www.pressreleasebulletin.com/endocrine-therapy-drugs-market-size/
Explore More Related Article: https://medium.com/@gauri.cmi01/the-global-training-market-growth-accelerated-by-leveraging-ai-and-analytics-technologies-6028c29126b3